New Targets in Inflammation

Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference held on April 15–16, 1996, in New Orleans, USA, supported by an educational grant from Boehringer Ingelheim

Häftad, Engelska, 2012

AvN. Bazan,Jack H. Botting,Sir John R. Vane,John R. Vane

1 429 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

The recent discovery that prostaglandins responsible for pain and other symptoms at inflammatory foci are synthesized by an inducible cyclooxygenase (COX-2) that is encoded by a gene distinct from that of the consti tutive enzyme (COX-I) provided a new target for therapy of RA.

Produktinformation

Utgivningsdatum2012-10-16
Mått155 x 235 x 10 mm
Vikt260 g
FormatHäftad
SpråkEngelska
Antal sidor147
Upplaga1996
FörlagSpringer
ISBN9789401062657

Tillhör följande kategorier

Farmakologi inom Medicin

Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids.

1 The history of anti-inflammatory drugs and their mechanism of action.- 2 Structure of prostaglandin H2 synthase-1 (COX-1) and its NSAID binding sites.- 3 Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs.- 4 Blockade of inflammatory hyperalgesia and cyclooxygenase-2.- 5 Brain COX-2 in experimental models of epilepsy and stroke: signalling pathways leading to enhanced expression.- 6 New highly selective cyclooxygenase-2 inhibitors.- 7 Characteristics of cyclooxygenase-1 and cyclooxygenase-2-deficient mice.- 8 X-ray crystal structure of human cyclooxygenase-2.- 9 Risk of gastrointestinal side effects caused by non-steroid anti-inflammatory drugs (NSAIDs).- 10 Expression and regulation of cyclooxygenase-2 in synovial tissues of arthritic patients.- 11 Differential target tissue presentation and COX-1/COX-2 inhibition by non-steroid anti-inflammatory drugs: a rationale for a new classification.- 12 Clinical experience with meloxicam, a selective COX-2 inhibitor.- 13 Enzymatic regulation of the prostaglandin response in a human model of inflammation.- 14 Cyclooxygenase-2 and intestinal cancer.- 15 Cytokines and adhesion molecules in the lung inflammatory response.- 16 Adhesion molecules as targets for therapy in rheumatoid arthritis.